With a market cap of $32.6 billion, San Diego, California-based ResMed Inc. (RMD) is a global leader in designing, ...

“For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can ...

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The ...

Resmed (RMD) announced the publication of a meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly ...

Despite good sleep being essential for our overall health, productivity, and relationships, millions worldwide struggle with ...

Resmed, a leader in sleep technology, unveiled its latest global health consumer campaign, ‘Say goodbye to your sleep monster’ via the aptly named independent creative agency Hopeful Monsters. To help ...

Resmed, a leader in health technology focused on sleep and respiratory care, has announced a significant brand evolution aimed at unifying its portfolio and enhancing direct consumer engagement.

Independent Advisor Alliance acquired a new stake in shares of ResMed Inc. (NYSE:RMD – Free Report) during the fourth quarter ...

Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.

ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.

CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine ...

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dy ...